Increased salivary syndecan-1 level is associated with salivary gland function and inflammation in patients with Sjögren’s syndrome

References

• Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjogren’s syndrome: what we know and what we should learn. J Autoimmun 2012;39:4–8.
   PubMed Web of Science ®Google Scholar
• Goules AV, Kapsogeorgou EK, Tzioufas AG. Insight into pathogenesis of Sjogren’s syndrome: dissection on autoimmune infiltrates and epithelial cells. Clin Immunol 2017;182:30–40.
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162–5.
   PubMedGoogle Scholar
• Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells 2007;24:153–66.
   PubMed Web of Science ®Google Scholar
• Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol 2012;31:3–16.
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Jalkanen M. Transcriptional regulation of Syndecan-1 expression by growth factors. Prog Nucleic Acid Res Mol Biol 1999;63:109–38.
   PubMed Web of Science ®Google Scholar
• Hayashida K, Johnston DR, Goldberger O, Park PW. Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem 2006;281:24365–74.
   PubMed Web of Science ®Google Scholar
• Gotte M. Syndecans in inflammation. FASEB J 2003;17:575–91.
   PubMed Web of Science ®Google Scholar
• Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, et al. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006;16:488–501.
   PubMed Web of Science ®Google Scholar
• Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 2010;277:3876–89.
   PubMed Web of Science ®Google Scholar
• Blokland SLM, Flessa CM, Van Roon JAG, Mavragani CP. Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sjogren’s syndrome. Rheumatology (Oxford). Published online. 5 March 2019. doi:https://doi.org/10.1093/rheumatology/key438.
   Web of Science ®Google Scholar
• Mason GI, Hamburger J, Bowman S, Matthews JB. Salivary gland expression of transforming growth factor beta isoforms in Sjogren’s syndrome and benign lymphoepithelial lesions. Mol Pathol 2003;56:52–9.
   PubMedGoogle Scholar
• Boras VV, Cikes N, Lukac J, Cekic-Arambasin A, Virag M, Bosnjak A. The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjogren’s syndrome. Coll Antropol 2004;28:305–9.
   PubMedGoogle Scholar
• Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in Sjogren’s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013;94:1079–89.
   PubMed Web of Science ®Google Scholar
• Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J, et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren’s syndrome. Arthritis Rheum 2001;44:2633–41.
   PubMed Web of Science ®Google Scholar
• Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y, et al. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren’s syndrome patients. Arthritis Rheum 2002;46:1585–94.
   PubMed Web of Science ®Google Scholar
• Perez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 2000;43:2807–17.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren’s syndrome. Matrix Biol 1998;17:335–47.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Kangaspunta P, Lindy O, Takagi M, Sorsa T, Segerberg M, et al. Collagenase in Sjogren’s syndrome. Ann Rheum Dis 1994;53:836–9.
   PubMed Web of Science ®Google Scholar
• Hoffman MP, Nomizu M, Roque E, Lee S, Jung DW, Yamada Y, et al. Laminin-1 and laminin-2 G-domain synthetic peptides bind syndecan-1 and are involved in acinar formation of a human submandibular gland cell line. J Biol Chem 1998;273:28633–41.
   PubMed Web of Science ®Google Scholar
• Gama-de-souza LN, Cyreno-Oliveira E, Freitas VM, Melo ES, Vilas-Boas VF, Moriscot AS, et al. Adhesion and protease activity in cell lines from human salivary gland tumors are regulated by the laminin-derived peptide AG73, syndecan-1 and beta1 integrin. Matrix Biol 2008;27:402–19.
   PubMed Web of Science ®Google Scholar
• Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859–66.
   PubMed Web of Science ®Google Scholar
• Almstahl A, Wikstrom M. Electrolytes in stimulated whole saliva in individuals with hyposalivation of different origins. Arch Oral Biol 2003;48:337–44.
   PubMed Web of Science ®Google Scholar
• Kang JY, Jang SJ, Lee WW, Jang SJ, Lee YJ, Kim SE. Evaluation of salivary gland dysfunction using salivary gland scintigraphy in Sjogren’s syndrome patients and in thyroid cancer patients after radioactive iodine therapy. Nucl Med Mol Imaging 2011;45:161–8.
   PubMedGoogle Scholar
• Daniels TE. Labial salivary gland biopsy in Sjogren’s syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147–56.
   PubMed Web of Science ®Google Scholar
• Umehara I, Yamada I, Murata Y, Takahashi Y, Okada N, Shibuya H. Quantitative evaluation of salivary gland scintigraphy in Sjorgen’s syndrome. J Nucl Med 1999;40:64–9.
   PubMed Web of Science ®Google Scholar
• Aksoy T, Kiratli PO, Erbas B. Correlations between histopathologic and scintigraphic parameters of salivary glands in patients with Sjogren’s syndrome. Clin Rheumatol 2012;31:1365–70.
   PubMed Web of Science ®Google Scholar
• Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjogren’s syndrome. Arch Med Res 2006;37:921–32.
   PubMed Web of Science ®Google Scholar
• Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, et al. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha. Biochem Biophys Res Commun 1990;171:610–7.
   PubMed Web of Science ®Google Scholar
• Bookman AA, Shen H, Cook RJ, Bailey D, McComb RJ, Rutka JA, et al. Whole stimulated salivary flow: correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjogren’s syndrome but not patients with sicca. Arthritis Rheum 2011;63:2014–20.
   PubMed Web of Science ®Google Scholar
• Vinagre F, Santos MJ, Prata A, Da Silva JC, Santos AI. Assessment of salivary gland function in Sjogren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 2009;8:672–6.
   PubMed Web of Science ®Google Scholar
• Fisher BA, Brown RM, Bowman SJ, Barone F. A review of salivary gland histopathology in primary Sjogren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis 2015;74:1645–50.
   PubMed Web of Science ®Google Scholar
• Hackett KL, Newton JL, Frith J, Elliott C, Lendrem D, Foggo H, et al. Impaired functional status in primary Sjogren’s syndrome. Arthritis Care Res (Hoboken) 2012;64:1760–4.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoo JJ, Yun CY, Kang EH, Lee HJ, Hyon JY, et al. The EULAR Sjogren’s syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren’s syndrome patients: in comparison with non-Sjogren’s sicca patients. Rheumatology (Oxford) 2013;52:2208–17.
   PubMed Web of Science ®Google Scholar
• Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjogren’s syndrome: promises and pitfalls. Clin Exp Rheumatol 2018;36:222–33.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kim JY, Baek IW, Kim WU, Cho CS. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus. J Rheumatol 2015;42:202–9.
   PubMed Web of Science ®Google Scholar
• Szyszko EA, Brun JG, Skarstein K, Peck AB, Jonsson R, Brokstad KA. Phenotypic diversity of peripheral blood plasma cells in primary Sjogren’s syndrome. Scand J Immunol 2011;73:18–28.
   PubMed Web of Science ®Google Scholar
• Mariette X, Criswell LA. Primary Sjogren’s syndrome. N Engl J Med 2018;378:931–9.
   PubMed Web of Science ®Google Scholar